Aligos Therapeutics (NASDAQ:ALGS) Posts Earnings Results, Misses Expectations By $0.92 EPS

Aligos Therapeutics (NASDAQ:ALGS) issued its quarterly earnings data on Wednesday. The company reported ($3.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92), Zacks reports. The company had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period last year, the company posted ($10.25) EPS.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock traded up $0.27 during midday trading on Friday, hitting $10.19. 108,249 shares of the company’s stock were exchanged, compared to its average volume of 39,795. The company has a market cap of $32.61 million, a P/E ratio of -0.50 and a beta of 2.11. The stock has a 50-day moving average price of $9.81 and a two-hundred day moving average price of $12.63. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $30.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).